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Abstract
Background The mucopolysaccharidoses are multisystem lysosomal storage diseases characterized by extensive skeletal defor-
mities, including skull abnormalities. The objective of this study was to determine the incidence of craniosynostosis in the
different mucopolysaccharidosis (MPS) types and its clinical consequences.
Methods In a prospective cohort study spanning 10 years, skull imaging and clinical evaluations were performed in 47 MPS
patients (type I, II, VI, and VII). A total of 215 radiographs of the skull were analyzed. The presence and type of craniosynostosis,
the sutures involved, progression over time, skull shape, head circumference, fundoscopy, and ventriculoperitoneal shunt (VPS)
placement data were evaluated.
Results Craniosynostosis of at least one suture was present in 77% of all 47MPS patients (≤ 6 years of age in 40% of all patients).
In 32% of all MPS patients, premature closure of all sutures was seen (≤ 6 years of age in 13% of all patients). All patients with
early closure had a more severe MPS phenotype, both in the neuronopathic (MPS I, II) and non-neuronopathic (MPS VI) patient
groups. Because of symptomatic increased intracranial pressure (ICP), a VPS was placed in six patients, with craniosynostosis as
a likely or certain causative factor for the increased pressure in four patients. One patient underwent cranial vault expansion
because of severe craniosynostosis.
Conclusions Craniosynostosis occurs in the majority of MPS patients. Since the clinical consequences can be severe and surgical
intervention is possible, skull growth and signs and symptoms of increased ICP should be monitored in both neuronopathic and
non-neuronopathic patients with MPS.
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Introduction
Mucopolysaccharidoses are lysosomal storage diseases
caused by deficiencies of glycosaminoglycan (GAG)-
degrading enzymes. The mucopolysaccharidoses are multi-
system disorders with a broad range of clinical manifesta-
tions, including extensive skeletal abnormalities (dysostosis
multiplex, joint contractures) and hydrocephalus (Neufeld
and Muenzer 2001; Dalla Corte et al. 2017). Neurological
decline due to GAG accumulation in the brain is seen in a
subset of patients with mucopolysaccharidosis (MPS) type I,
II, III, and VII (Neufeld and Muenzer 2001; Shapiro et al.
2017).
In healthy individuals, the skull expands by growth from
the sutures up to the age of 6 years. After the age of 6 years,
both sutural and appositional growth takes place (Cohen
1988, 1993). The metopic suture closes between the age of
3 and 9 months (Vu et al. 2001). The sagittal, coronal, and
lambdoid sutures begin to close much later, around, respec-
tively, 22, 24, and 26 years of age (Cohen 1993). If one or
more suture(s) close(s) at an earlier age, this can result in
growth stagnation and/or an abnormal skull shape. This pre-
mature fusion (craniosynostosis) can be classified as simple
(one fused suture) or complex (multiple sutures involved),
primary (sutural biology abnormality) or secondary (due to
external influences), and as part of a syndrome or isolated
(Moosa and Wollnik 2016).
Early closure of each suture results in a different
shape of the skull; for example, early closure of the
sagittal suture results in an elongated and narrow skull
(scaphocephaly) and early closure of the lambdoid su-
tures results in occipital flattening (pachycephaly)
(Persing et al. 1989). Early-onset craniosynostosis, de-
fined as closure of sutures before the age of 6 years,
can restrict skull growth and can cause elevated intra-
cranial pressure (ICP), which in turn can result in visual
impairment (de Jong et al 2010). Therefore early recog-
nition of craniosynostosis is of great importance. Timely
surgical intervention can provide space for the brain to
grow, preserving development and vision (Speltz et al
2004)
Up till now, only two small cross-sectional studies in-
vestigated the prevalence of craniosynostosis in MPS pa-
tients. They found secondary craniosynostosis in 19% (7
out of 36) of severe MPS II patients and 11% (2 out of
18) of MPS IVA patients. In addition, three case reports
describe the presence of craniosynostosis in MPS (types I
and VI) (Taylor et al. 1978; Cohen 1993; Brisman et al.
2004; Manara et al . 2011; Ziyadeh et al . 2013;
Bhattacharya et al. 2014; Sadashiva et al. 2015). The in-
cidence and type of craniosynostosis in MPS, the devel-
opment over time, severity, and clinical consequences
have not been studied. In our prospective study, this was
systematically evaluated in a relatively large cohort of
patients with MPS I, II, VI, and VII.
Methods
Patients
From 2007 onwards, all pediatric patients with MPS
(type I, II, VI, and VII) treated at the Center for
Lysosomal and Metabolic Diseases of the Erasmus MC,
Rotterdam, the Netherlands, were included in a prospec-
tive cohort study. In all patients, the diagnosis of MPS
had been confirmed by the measurement of enzyme de-
ficiency in leukocytes or fibroblasts and by DNA analy-
sis. Yearly evaluation was done according to a standard-
ized follow-up protocol, which included medical history
taking, physical and neurological examination, skull ra-
diographs, and ophthalmological examinations. Available
data from 2002 till 2007 were added retrospectively. The
study was approved by the Medical Ethical Review
board at the Erasmus MC.
Radiographic evaluation of sutures and skull shape
Skull radiographs [anterior posterior (AP) and lateral]
were obtained yearly up to the age of 18 years.
Radiographs of patients with a ventriculoperitoneal
shunt (VPS) were excluded after drain placement, as
the drain itself can induce secondary closure of one or
more sutures in proximity to the drain (Ryoo et al.
2014). Furthermore, the postoperative radiographs of a
patient who underwent cranial surgery were excluded
from the analysis.
Each radiograph was evaluated by two independent ob-
servers (craniosynostosis expert and plastic surgeon professor
IMJM and lysosomal expert and metabolic pediatrician EO).
In each radiograph, three sutures (coronal, sagittal, and
lambdoid) were scored as open, partially closed, or closed.
The metopic suture was not analyzed as it physiologically
closes between the age of 3 and 9 months and, for most pa-
tients, radiographs were not available at such an early age (Vu
et al. 2001).
For each MPS type (I, II, VI, and VII), the propor-
tion of patients with craniosynostosis was determined.
Furthermore, the proportion of patients with one closed
suture and with two or more closed sutures was deter-
mined, and the order in which the sutures closed was
analyzed. For each patient, the shape of the skull was
described using the last available radiograph. Of three
patients with craniosynostosis, three-dimensional com-
puted tomography (CT) scans of the skull were
available.
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Head circumferences, ophthalmological and physical
examination
Head circumference was measured at least yearly and the
measurements closest to the evaluated radiographs of the skull
were used for analysis. At physical examination, head shape
and facial features were examined.
The presence of raised ICP was evaluated by fundoscopy
during yearly ophthalmological assessments, unless fundos-
copy could not be reliably performed due to corneal clouding
or behavioral problems.
VPS placement
Of the MPS patients who received a VPS, the following
parameters at the time of placement were determined:
age, VPS indication [clinical features, brain imaging,
and cerebrospinal fluid pressure (CSF)], head circumfer-
ence, head shape, presence or absence of craniosynosto-
sis, and result of fundoscopy.
Statistics
All data are presented as median and range, unless otherwise
stated.
Results
Patient data and characteristics
Forty-seven patients with MPS (type I, II, VI, and VII) were
included in this study (72% male patients). The median age at
diagnosis was 2.8 (range 0–12) years. Table 1 shows the dis-
ease type and severity, mutation(s), gender, age at diagnosis,
age at first and last radiograph, and skull shape for each
patient.
Skull radiographs
A total of 215 skull radiographs were analyzed. The first avail-
able radiograph was taken at 4.2 (range 0–12.4) years of age
for the entire MPS patient group. The follow-up period was
3.4 (range 0.1–9.1) years (Table 1).
Prevalence of craniosynostosis in MPS
Craniosynostosis of at least one suture was present in
77% of all 47 MPS patients and in 40% of patients, this
occurred before the age of 6 years (Figs. 1 and 2).
Table 2 shows the prevalence of craniosynostosis, the
number of sutures involved, and the resulting head
shape for each MPS type.
Sutures involved, progression over time, and severity
Of all MPS patients, 9% had premature (partial) closure
of only one suture. In 66% of all MPS patients, two or
three sutures partially or fully closed prematurely
(Fig. 1 and Table 2). The longitudinal data on closure
of each suture in each individual MPS patient are
depicted in Fig. 2. In most cases, two or three sutures
were already (partially) closed at the time the first ra-
diograph was made (Fig. 2). The coronal suture was
never the first to close (Fig. 1).
In 32% of all MPS patients, premature closure of all sutures
was seen (≤ 6 years of age in 13% of all patients; Table 2). All
these patients with early closure (≤ 6 years of age) had a more
severe MPS phenotype.
Skull shape
No specific skull shape abnormality (normocephaly)
could be detected in 51% of all MPS patients (Tables 1
and 2). Despite a normal skull shape, all sutures had
closed before the age of 6 years in two patients (MPS
VI, patient nos. 1 and 5); this is also referred to as
pansynostosis (Foo et al. 2010).
Scaphocephaly was seen in 26% of all MPS patients. In 8
of these 12 patients, closure of the sagittal suture had occurred
around or before the age of 6 years. Pachycephaly was detect-
ed in 23% of all MPS patients. Pachycephaly with
scaphocephaly was seen in one patient (MPS I, patient no.
2). Plagiocephaly at the right anterior side of the head was
seen in one MPS II patient (Fig. 3a, patient no. 10).
Illustrative cases of craniosynostosis in MPS
Figure 3 shows photographs, skull X-rays, 3D CT scans,
and MRI of the cerebrum of an MPS II patient (patient
no. 10) (Fig. 3a) with bulging anterior fontanel due to
craniosynostosis, an MPS VI patient (patient no. 8)
(Fig. 3b) with frontal bossing and scaphocephaly due
to craniosynostosis, and an adult MPS VI patient (broth-
er of patient no. 4) (Fig. 3c). This adult patient died
unexpectedly at 25 years of age as a result of a respi-
ratory tract infection in an already highly compromised
respiratory setting. Figure 3c shows macroscopic pic-
tures from the brain autopsy with impression of the
sinus transversus in the skull (X-skull) and impression
of the brain gyri in the frontal bone, resulting from
raised ICP earlier in life.
Head circumferences
Data from at least one head circumferencesmeasurement were
available for 94% of all MPS patients. Only two patients had a
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Fig. 1 Suture closure in the different mucopolysaccharidosis (MPS)
types. Kaplan–Meier curves of open suture(s) (coronal: A, lambdoid: B,
and sagittal: C) byMPS subtype (types I, II, and VI ). 1.0 means 100% of
patients with open or partially closed suture, 0 means suture closed in all
patients. MPS VII patients were not included in the graph because of the
low number (n = 2). In healthy individuals, the sagittal, coronal, and
lambdoid sutures begin to close around, respectively, 22, 24, and 26 years
of age
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head circumference outside the normal reference range
(− 2SD). Both were MPS VI patients (patient nos. 1 and 5)
in whom all sutures closed before the age of 6 years with
stagnation (arrest) of skull growth. After the age of 6 years,
their head circumferences started to increase again, in line
with appositional growth of the skull. Supplemental Fig. 1
Fig. 2 Craniosynostosis by MPS type in individual patients. For each
MPS type, the suture closure over time is shown. Each suture is
depicted by a symbol: coronal: square; lambdoid: circle; sagittal:
diamond. Closure status is indicated by the filling of the symbol:
transparent: open suture(s); shaded: partial closure; black: completely
closed. For MPS I, II, and VI, the most severe phenotypes are at the top
and the least severe phenotypes are at the bottom of the graph.
Abbreviations in the graph: Pt.: patient; N: neuronopathic; NN: non-
neuronopathic R: rapidly progressive; S: slowly progressive. Right:
skull shape; N: normocephaly; S: scaphocephaly; P: pachycephaly; B:
brachycephaly; Pl*: plagiocephaly. A black line is drawn at the age of 6
years; if suture closure occurs before the age of 6 years, this is regarded as
early-onset craniosynostosis
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Table 2 Prevalence of craniosynostosis, the number of sutures involved, and the resulting skull shape by mucopolysaccharidosis (MPS) type
Total MPS MPS I MPS II MPS VI MPS VII
≥ 1 Suture closed; n/total (%) 36/47 (77%) 10/14 (71%) 10/15 (67%) 15/16 (94%) 1/2 (50%)
≥ 1 Suture closed ≤ 6 years old; n/total (%) 19/47 (40%) 6/14 (43%) 6/15 (40%) 7/16 (44%) 0/2 (0%)
1 Suture closed; n/total (%) 4/47 (9%) 2/14 (14%) 0/15 (0%) 1/16 (6%) 1/2 (50%)
> 2 Sutures closed; n/total (%) 31/47 (66%) 7/14 (50%) 10/15 (67%) 14/16 (88%) 0/2 (0%)
All sutures closed; n/total (%) 15/47 (32%) 2/14 (14%) 4/15 (27%) 9/16 (56%) 0/2 (0%)
All sutures closed ≤ 6 years old; n/total (%) 6/47 (13%) 2/14 (13%) 1/15 (7%) 3/16 (19%) 0/2 (0%)
All sutures open; n/total (%) 11/47 (23%) 4/14 (29%) 5/15 (33%) 1/16 (6%) 1/2 (50%)
Skull shape; n/total (%)* N: 24/47 (51%) N: 4/14 (29%) N: 9/15 (60%)^ N: 10/16 (63%) N: 1/2 (50%)
S: 12/47 (26%) S: 6/14 (43%)# S: 2/15 (13%)^ S: 4/16 (25%) S: 0/2 (0%)
P: 11/47 (23%) P: 5/14 (36%)# P: 3/15 (20%)^ P: 2/16 (13%) P: 1/2 (50%)
*N: Normocephalic; S: scaphocephalic; P: pachycephalic
#One patient had both scaphocephalic and pachycephalic head shape
^One patient had only plagiocephaly at the right anterior side of the head and, therefore, the data of one patient are missing
Fig. 3 Three illustrative cases of craniosynostosis in MPS. a Patient no.
10, MPS II, 1.5 years old. Photographs show the distinct facial features,
MRI T2 FLAIR and 3D CT scan shows the bulging anterior fontanel
(volcano sign) with plagiocephaly at the right anterior side of the head.
3D CT scan shows the premature closure of the left coronal suture, the
sagittal suture, and both lambdoid sutures. b Patient no. 8, MPS VI, 3.3
years old. Skull X-ray shows frontal bossing and scaphocephaly. X-skull
and 3D CT scan show craniosynostosis of the metopic, both lambdoid
and sagittal sutures. On MRI T2 FLAIR of the cerebrum, there are no
signs of increased intracranial pressure (ICP). c MPS VI patient, 24 years
old. Photographs and skull X-rays show distinct facial features,
scaphocephaly, and sinus transversus impression in the skull.
Macroscopic pictures from the autopsy at age 25 years show (in red)
impressions of the brain gyri in the frontal bones and abnormal thin
bone layer. In blue (top to bottom), abnormal deep olfactory furrow,
sella turcica, and severe narrow foramen magnum. In green, thickened
skull. The white arrow shows where there is an impression of the skull in
the brain
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shows skull and height growth curves and photo- and radio-
graphs of one of these patients (MPS VI, patient no. 1).
Ophthalmic examination
Fundoscopy data were available for 85% of all MPS patients.
Two patients had papilledema. In one of them, craniosynosto-
sis was recognized at that time as the cause of increased ICP.
Occipital cranial vault expansion with fronto-supraorbital
remodulation surgery was performed at the age of 1 year
and 9 months (MPS II, patient no. 10, Fig. 3a). In the second
patient (MPS VI, patient no. 7), edema was mild, there were
no clinical signs of increased ICP, and skull growth was nor-
mal; thus, an intervention was deemed unnecessary.
VPS placement
In six patients, a VPS was placed at a median age of 5.4
(range 2–7.5) years, because of suspected elevated ICP
(Table 3). Fundoscopy was performed or attempted in
three patients before VPS placement. Two patients had
no papilledema and in the other patient, fundoscopy was
not possible due to corneal clouding or abnormal behav-
ior. In five of the six patients, CT or MRI scan of the
brain prior to VPS placement showed progressive hydro-
cephalus. They had clinical symptoms caused by the in-
creased ICP, such as neurological decline (faster than the
expected decline due to GAG accumulation in the brain),
headache, and epilepsy. In four patients, the SD value of
Fig. 3 (continued)
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the head circumferences increased before VPS placement.
In one patient (MPS II, patient no. 6), this occurred in a
relatively short time (increase from 1 to 4SD), with only
slightly elevated CSF pressure measured at the time of
VPS placement. In one patient (MPS VI, patient no. 3),
the head circumferences SD value declined prior to drain
placement. This patient had partial closure of the
lambdoid suture and complete closure of the sagittal su-
ture with elevated CSF pressure (30–45 cm H2O) at the
time of VPS placement (Fig. 2). We concluded that cra-
niosynostosis, in combination with hydrocephalus, most
likely contributed to the increased ICP in four out of the
six patients with a VPS (Table 3; MPS I, patient nos. 2, 4,
and 6; MPS VI, patient no. 3). In the fifth patient,
craniosynostosis was not present (MPS II, patient no. 5)
and in the sixth patient (MPS II, patient no. 6), no radio-
graph in the 2 years before shunt placement was made.
One year after VPS placement, all sutures were closed in
this patient (Fig. 2), suggesting this had already, at least
partially, occurred before drain placement.
Discussion
This is the first long-term prospective study assessing skull
suture closure and its consequences in patients with MPS I, II,
VI, and VII. Our results show that craniosynostosis occurs at a
very high frequency in these different types of MPS.
Fig. 3 (continued)
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Premature closure of at least one suture was present in 77% of
patients, with suture closure before the age of 6 years in 40%
of patients. In the general population, non-syndromic cranio-
synostosis occurs with a frequency between 0.4 and 1.0 per
1000 live births, while syndromic craniosynostosis is even
more rare (Shuper et al. 1985; French et al. 1990; Singer et
al. 1999; Boulet et al. 2008; Tahiri et al. 2017). The incidence
found in the current study may even be an underestimation,
because only one skull radiograph was available for 43% of
our patients. In addition, the median follow-up was relatively
short (3.4 years).
Consistent with syndromic craniosynostosis, the majority
of MPS patients (66%) had early closure of more than one
suture, with involvement of the lambdoid and coronal sutures
(Twigg and Wilkie 2015).
An abnormal head shape resulting from early suture clo-
sure was seen in about half of all studied MPS patients, and
scaphocephaly and pachycephaly were the most frequently
observed. The trichonocephalic head shape which is seen by
early closure of the metopic suture was not present in ourMPS
population.
Scaphocephaly due to premature closure of the sagittal su-
ture was often (21%) seen in the severely affected MPS I (6
patients) and MPS VI (4 patients). In 13 % of all MPS pa-
tients, all sutures closed at an early age (pansynostosis), with
normal head shape in two patients. Pansynostosis can easily
be overlooked in these children, as their small head size can be
interpreted as normal because they often have a small stature.
In MPS patients in whom growth stagnation of the head oc-
curs (example in Supplemental Fig. 1), further investigation is
warranted, regardless of whether this is in line with their body
length growth.
In MPS, evaluation of the consequences of craniosynosto-
sis is complicated because increased ICP in this condition is
often multifactorial. Hydrocephalus in MPS arises from the
accumulation of GAGs in cells of the brain (ventricles, arach-
noid villi), in supporting structures (meninges or spinal col-
umn), or results from venous hypertension related to the flow-
limiting morphological changes in the skull base (Fig. 3c) and
craniocervical junction (Alden et al. 2017; Dalla Corte et al.
2017). Moreover, the detection of clinical symptoms of raised
ICP, such as visual decline or headache and nausea, can be
difficult to detect, especially in the cognitively impaired
patients.
Another pitfall in the evaluation of the consequences of
craniosynostosis in MPS is the assessment of increased ICP
in these disorders. Papilledema is not always present in MPS
patients with increased ICP (for example, MPS VI patients,
patient no. 3), while, vice versa, it can be present in patients
with normal ICP, as a result of GAG accumulation in the
sclera or optic nerve (Beck and Cole 1984; Collins et al.
1990). Expansion of the ventricles in response to increased
ICP is often not present in MPS patients, as the ventriclesTa
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are stiff due to the GAG accumulation, while enlarged ventri-
cles can be present without raised ICP in the neuronopathic
MPS patients due to brain atrophy (Alden et al. 2017). Thus,
in the case of high clinical suspicion of increased ICP in MPS
patients, thorough examination using different diagnostic mo-
dalities (including lumbar punction and/or 24-h ICP monitor-
ing) should be carried out before dismissing this diagnosis.
When hydrocephalus and craniosynostosis occur in the
same MPS patient, this can result in severely elevated ICP,
since expansion of the skull in response to increase in pressure
cannot take place. This is illustrated by the examples in our
studied cohort. Patient 6 with MPS II did not have craniosyn-
ostosis and his skull could, therefore, expand to + 4SD in
response to the occurring hydrocephalus, resulting in near-
normal ICP. In contrast, patient 3 with MPS VI, in whom all
sutures closed at a young age leading to skull growth stagna-
tion, high ICP was found, potentially as a result of the com-
bination of a CSF drainage problem and craniosynostosis.
In our patient cohort, craniosynostosis resulting in in-
creased ICP also occurred in the non-neuronopathic MPS VI
patients. This is demonstrated in the adult MPS VI patient in
Fig. 3c, where the indentations of the brain in the skull, ob-
served upon autopsy, indicate raised ICP earlier in life. In non-
neuronopathic MPS patients, extensive GAG accumulation in
the brain is not observed, and neurocognitive developmental
is usually described as normal (Neufeld and Muenzer 2001;
Valayannopoulos et al. 2010). Interestingly, we previously
described mild cognitive impairment in three MPS VI patients
(Ebbink et al. 2016). In this study, it is shown that two of these
patients had pansynostosis and one had closure of two sutures
before the age of 6 years (patient nos. 1, 5, and 6). Whether
craniosynostosis indeed contributed to the cognitive distur-
bances in these patients remains to be determined by studying
larger numbers of non-neuronopathic patients.
In other craniosynostosis syndromes such as Apert and
Pfeiffer syndromes, suture closure occurs in utero, resulting
in increased ICP very early in life (Mathijssen et al. 1999;
Lajeunie et al. 2006). In these cases, guidelines for treatment
in the form of surgical cranial vault expansion are clear
(Mathijssen 2015). In MPS, suture closure seems to occur in
early childhood; thus, the clinical consequences are likely to
be less severe. Increased ICP in MPS can be multifactorial;
treatment decisions should, thus, be made for each case indi-
vidually, taking into account all aspects of the disorder. In the
non-neuronopathic MPS patients, surgical cranial vault ex-
pansion might be an option in early childhood. In the
neuronopathic patients, placement of a VPS to decrease ICP
may be the treatment of choice since ongoing neurocognitive
decline due to intracerebral GAG accumulation is to be ex-
pected and surgery for craniosynostosis imposes a large bur-
den on the child.
In order to prevent complications of craniosynostosis, we
recommend to monitor both skull growth by measuring head
circumferences and to perform radiographs of the skull yearly
in both neuronopathic and non-neuronopathic MPS patients
until at least the age of 6 years.
Conclusion
Craniosynostosis occurs in the majority of mucopolysa
ccharidosis (MPS) patients. Since the clinical consequences
can be severe and surgical intervention is possible, skull
growth and signs and symptoms of increased intracranial pres-
sure (ICP) should be monitored in both neuronopathic and
non-neuronopathic patients with MPS.
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